Stockreport

Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH [Yahoo! Finance]

Mosaic Company (The)  (MOS) 
Last mosaic company (the) earnings: 2/19 04:42 pm Check Earnings Report
US:NYSE Investor Relations: investors.mosaicco.com
PDF molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MOSAIC, the company's Phase 2a [Read more]